Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Xencor, Inc. (XNCR : NSDQ)

• Company Description    Xencor Inc. is a clinical-stage biopharmaceutical company. It develops antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer. Xencor Inc. is based in Monrovia, California. Number of Employees: 260

• Price / Volume Information    Yesterday's Closing Price: $25.18 Daily Weekly Monthly 20 Day Moving Average: 1,367,683 shares Shares Outstanding: 74.35 (millions) Market Capitalization: $1,872.21 (millions) Beta: 0.89 52 Week High: $30.61 52 Week Low: $10.38 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 5.44% 6.56% 12 Week 17.17% 14.31% Year To Date 64.47% 50.76%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 465 NORTH HALSTEAD STREET SUITE 200 - PASADENA,CA 91107 USA ph: 626-305-5900 fax: 626-305-0350 cliles@xencor.com http://www.xencor.com

• General Corporate Information    Officers Bassil I. Dahiyat - Chief Executive Officer; President and Director Bart Jan Cornelissen - Senior Vice President & Chief Financial Officer A. Bruce Montgomery - Director Kurt Gustafson - Director Kevin C. Gorman - Director Peer Information Xencor, Inc. (GSAC) Xencor, Inc. (CASIF) Xencor, Inc. (ALCD.) Xencor, Inc. (OMNN) Xencor, Inc. (CGPI.) Xencor, Inc. (CATX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-DRUGS Sector: Medical CUSIP: 98401F105 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/26 Next Expected EPS Date: 11/04/26 Share - Related Items Shares Outstanding: 74.35 Most Recent Split Date: (:1) Beta: 0.89 Market Capitalization: $1,872.21 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.93 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-3.05 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 8.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: 30.88% Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/04/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 3.71 Price/Cash Flow: - Price / Sales: 17.84 EPS Growth vs. Year Ago Period: 29.27% vs. Previous Quarter: 83.04% Sales Growth vs. Year Ago Period: 17.46% vs. Previous Quarter: 1,034.21% ROE 09/30/26 - - 06/30/26 - -28.66 03/31/26 - -28.77 ROA 09/30/26 - - 06/30/26 - -20.38 03/31/26 - -20.52 Current Ratio 09/30/26 - - 06/30/26 - 6.39 03/31/26 - 6.57 Quick Ratio 09/30/26 - - 06/30/26 - 6.39 03/31/26 - 6.57 Operating Margin 09/30/26 - - 06/30/26 - -155.59 03/31/26 - -177.10 Net Margin 09/30/26 - - 06/30/26 - -155.59 03/31/26 - -177.10 Pre-Tax Margin 09/30/26 - - 06/30/26 - -153.23 03/31/26 - -174.61 Book Value 09/30/26 - - 06/30/26 - 6.79 03/31/26 - 6.96 Inventory Turnover 09/30/26 - - 06/30/26 - - 03/31/26 - - Debt-to-Equity 09/30/26 - - 06/30/26 - 0.00 03/31/26 - 0.00 Debt-to-Capital 09/30/26 - - 06/30/26 - 0.00 03/31/26 - 0.00

Powered by Zacks Investment Research ©